# To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis

> **NCT04566666** · PHASE2 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 263 (actual)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** Placebo
- **DRUG:** SCD-044_Low Dose (Dose 1)
- **DRUG:** SCD-044_Intermediate Dose (Dose 2)
- **DRUG:** SCD-044_High Dose (Dose 3)

## Key facts

- **NCT ID:** NCT04566666
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-25
- **Primary completion:** 2024-11-20
- **Final completion:** 2025-08-27
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04566666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04566666, "To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04566666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*